David Jin

Insider Reports History

Reporting-owner location: Waltham, MA
Latest reporting-owner signature: /s/ David Jin
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for David Jin

Form 4 holding Chief Financial Officer

Fortress Biotech, Inc.

Security class: Common Stock, par value $0.001
Shares / value: 1,251,571
Estimated value: $4,580,749
Report date: 01 Apr 2026
Price: $3.66
Ownership: Direct

Form 4 holding Interim PFO and COO

AVENUE THERAPEUTICS, INC.

Security class: COMMON STOCK, PAR VALUE $0.0001
Shares / value: 65,000
Estimated value: $9,100
Report date: 23 Sep 2024
Price: $0.1400
Ownership: Direct

Form 4 holding Director

MUSTANG BIO, INC.

Security class: COMMON STOCK, PAR VALUE $0.0001
Shares / value: 286
Estimated value: $275
Report date: 30 Dec 2025
Price: $0.9620
Ownership: Direct

Insider Reports Filed by David Jin

4 FBIO

Fortress Biotech, Inc.

Report period: 01 Apr 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 01 Apr 2026, 16:05
Role: Chief Financial Officer
Next action: Open filing details

4 MBIO

MUSTANG BIO, INC.

Report period: 30 Dec 2025
Transactions: 1
Transaction value: +$238
Accepted by SEC: 30 Dec 2025, 16:15
Role: Director
Next action: Open filing details

4 FBIO

Fortress Biotech, Inc.

Report period: 01 Oct 2025
Transactions: 1
Transaction value: +$3,549
Accepted by SEC: 02 Oct 2025, 16:30
Role: Chief Financial Officer
Next action: Open filing details

4 FBIO

Fortress Biotech, Inc.

Report period: 01 Apr 2025
Transactions: 1
Transaction value: +$6,078
Accepted by SEC: 01 Apr 2025, 16:20
Role: Chief Financial Officer
Next action: Open filing details

4 FBIO

Fortress Biotech, Inc.

Report period: 19 Dec 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 23 Dec 2024, 16:30
Role: Chief Financial Officer
Next action: Open filing details

3 MBIO

MUSTANG BIO, INC.

Report period: 23 Oct 2024
Transactions: 0
Transaction value: $0
Accepted by SEC: 29 Oct 2024, 16:05
Role: Director
Next action: Open filing details

4 FBIO

Fortress Biotech, Inc.

Report period: 01 Oct 2024
Transactions: 1
Transaction value: +$3,224
Accepted by SEC: 01 Oct 2024, 16:15
Role: Chief Financial Officer
Next action: Open filing details

4 ATXI

AVENUE THERAPEUTICS, INC.

Report period: 23 Sep 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 25 Sep 2024, 16:53
Role: Interim PFO and COO
Next action: Open filing details

4 FBIO

Fortress Biotech, Inc.

Report period: 10 Jul 2024
Transactions: 1
Transaction value: +$3,750
Accepted by SEC: 12 Jul 2024, 08:42
Role: Chief Financial Officer
Next action: Open filing details

4 FBIO

Fortress Biotech, Inc.

Report period: 01 Apr 2024
Transactions: 1
Transaction value: +$3,998
Accepted by SEC: 02 Apr 2024, 16:06
Role: Chief Financial Officer
Next action: Open filing details

4 FBIO

Fortress Biotech, Inc.

Report period: 20 Dec 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 22 Dec 2023, 16:05
Role: Chief Financial Officer
Next action: Open filing details

4 ATXI

AVENUE THERAPEUTICS, INC.

Report period: 30 Jun 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 05 Jul 2023, 16:09
Role: Interim PFO and COO
Next action: Open filing details

4 FBIO

Fortress Biotech, Inc.

Report period: 10 Feb 2023
Transactions: 1
Transaction value: +$30,000
Accepted by SEC: 14 Feb 2023, 15:06
Role: Chief Financial Officer
Next action: Open filing details

4 FBIO

Fortress Biotech, Inc.

Report period: 30 Nov 2022
Transactions: 1
Transaction value: +$2,800
Accepted by SEC: 02 Dec 2022, 15:14
Role: Chief Financial Officer
Next action: Open filing details

4 FBIO

Fortress Biotech, Inc.

Report period: 26 Oct 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 28 Oct 2022, 17:02
Role: Chief Financial Officer
Next action: Open filing details

3 FBIO

Fortress Biotech, Inc.

Report period: 16 Aug 2022
Transactions: 0
Transaction value: $0
Accepted by SEC: 25 Aug 2022, 16:02
Role: Chief Financial Officer
Next action: Open filing details

3 ATXI

AVENUE THERAPEUTICS, INC.

Report period: 11 May 2022
Transactions: 0
Transaction value: $0
Accepted by SEC: 25 May 2022, 16:05
Role: Int. PEO, Int. PFO, and COO
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .